Business Description
Cue Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US22978P1066
Share Class Description:
CUE: Ordinary SharesTotal Employee Number:
29Description
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.76 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.23 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -7.23 | |||||
Beneish M-Score | 1.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 102.5 | |||||
3-Year EBITDA Growth Rate | 45.1 | |||||
3-Year EPS without NRI Growth Rate | 42.8 | |||||
3-Year FCF Growth Rate | 41.9 | |||||
3-Year Book Growth Rate | -43.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.93 | |||||
9-Day RSI | 71.48 | |||||
14-Day RSI | 66.14 | |||||
3-1 Month Momentum % | 85.03 | |||||
6-1 Month Momentum % | 157.61 | |||||
12-1 Month Momentum % | 16.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.57 | |||||
Quick Ratio | 3.57 | |||||
Cash Ratio | 2.22 | |||||
Days Sales Outstanding | 32.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.9 | |||||
Shareholder Yield % | -17.78 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -59.83 | |||||
Net Margin % | -59.65 | |||||
EBITDA Margin % | -46.81 | |||||
FCF Margin % | -75.17 | |||||
OCF Margin % | -74.72 | |||||
ROE % | -113.47 | |||||
ROA % | -58.21 | |||||
ROIC % | -120.73 | |||||
3-Year ROIIC % | -322.2 | |||||
ROC (Joel Greenblatt) % | -380.02 | |||||
ROCE % | -97.62 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.13 | |||||
PB Ratio | 5.54 | |||||
Price-to-Tangible-Book | 5.54 | |||||
EV-to-EBIT | -7.51 | |||||
EV-to-EBITDA | -9.24 | |||||
EV-to-Revenue | 4.32 | |||||
EV-to-Forward-Revenue | 1.83 | |||||
EV-to-FCF | -5.75 | |||||
Price-to-GF-Value | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 6.99 | |||||
| Price-to-Net-Cash | 16.87 | |||||
Earnings Yield (Greenblatt) % | -13.32 | |||||
FCF Yield % | -15.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cue Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 32.731 | ||
| EPS (TTM) ($) | -5.58 | ||
| Beta | 3.0941 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 147.01 | ||
| 14-Day RSI | 66.14 | ||
| 14-Day ATR ($) | 4.552899 | ||
| 20-Day SMA ($) | 29.209 | ||
| 12-1 Month Momentum % | 16.67 | ||
| 52-Week Range ($) | 4.971 - 45.5 | ||
| Shares Outstanding (Mil) | 4.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cue Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cue Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 28.62 (+14.62%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 29.47 (-0.17%) | ||
| 0.0333333:1 Stock Split | 2026-04-24 | 16.63 (-4.45%) | ||
| General meeting for 2026 | 2026-04-13 09:00 | 15.06 (+68.14%) | ||
| R&D Day | 2026-04-07 10:00 | 5.31 (-0.56%) | ||
| Annual report for 2025 | 2026-03-16 | 8.51 (-4.80%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 8.51 (-4.80%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 20.49 (+0.44%) |
Show
Entries
Cue Biopharma Inc Frequently Asked Questions
What is Cue Biopharma Inc(CUE)'s stock price today?
The current price of CUE is $36.78. The 52 week high of CUE is $45.50 and 52 week low is $4.97.
When is next earnings date of Cue Biopharma Inc(CUE)?
The next earnings date of Cue Biopharma Inc(CUE) is 2026-08-12 Est..
Does Cue Biopharma Inc(CUE) pay dividends? If so, how much?
Cue Biopharma Inc(CUE) does not pay dividend.
Guru Commentaries on NAS:CUE
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) | 2022-11-17 |
Articles on Cue Biopharma Inc
Headlines
See More- 1
Jul 10, 2026
Cue Biopharma to raise $50M in oversubscribed private placement
Seeking Alpha • 3:08am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers